

Special Issue

Targeting Cyclin-Dependent Kinases in Human Cancers

Message from the Guest Editor

Cell cycle dysregulation is a hallmark of cancer. In normal cells, Cyclin-dependent kinases (CDKs) govern transition from G1 to S-phase finally enabling proliferation.

Quite reasonably, pharmacologic inhibition of CDKs has great therapeutic potential for both solid tumors and hematological malignancies.

Emerging evidence reveals that a holistic view of both tumor cells and the tumor microenvironment is crucial for the rationale application of CDKi.

This special issue will provide a comprehensive overview and novel insights on antitumoral and immune-stimulating effects of CDKi, underlying mechanisms of response, strategies to combat drug resistance and the potential risk of developing secondary malignancies at later stages that improve our understanding for subsequent clinical application.

Guest Editor

Dr. Claudia Maletzki

Universitätsmedizin Rostock Zentrum für Innere Medizin, Universität Rostock, Rostock, Germany

Deadline for manuscript submissions

closed (31 March 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/44840

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)